Pfizer’s Chief Vaccine Officer, Dr. Kathrin Jansen, is at the center of a controversy involving the US government’s decision to redraft its policy on gain of function research. According to Project Veritas, Dr. Jansen was asked by the US government to provide input on the redrafting of the policy.
Gain of function research is a controversial type of research that involves manipulating viruses and other pathogens to make them more infectious or more resistant to treatments. This type of research has been widely criticized due to its potential to create more dangerous pathogens that could be used in biowarfare.
Dr. Jansen has been a vocal advocate for the use of gain of function research. She believes that it is necessary to better understand how viruses and other pathogens evolve and how to develop treatments and vaccines for them.
However, her involvement in the redrafting of the policy has raised concerns among some experts. They argue that Dr. Jansen’s involvement could lead to a policy that is more favorable to the pharmaceutical industry, as opposed to one that focuses on the safety of the public.
The US government has yet to release the details of the redrafted policy, but the controversy has already sparked a debate over the role of the pharmaceutical industry in shaping public health policy.
Critics of the pharmaceutical industry argue that it has too much influence in the policy-making process. They point to the fact that Dr. Jansen was asked to provide input on the redrafting of the policy as evidence of this influence.
Proponents of the pharmaceutical industry, on the other hand, argue that the industry has an important role to play in public health policy. They argue that the industry’s expertise and knowledge are essential in developing safe and effective treatments and vaccines.
The controversy surrounding Dr. Jansen’s involvement in the redrafting of the gain of function research policy is likely to continue until the US government releases the details of the new policy. Until then, the debate over the role of the pharmaceutical industry in public health policy will likely continue.